Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

• ClinicalTrials.gov Identifier: NCT03551249
• Recruitment Status: Completed
• First Posted: June 11, 2018
• Last Update Posted: March 5, 2024
• Sponsor: InSightec
• Information provided by (Responsible Party): InSightec

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.

Condition or disease	Intervention/treatment	Phase
Glioma; Glioblastoma	Device: Focused ultrasound (FUS)	Not Applicable

Detailed Description:

This is a prospective, multi-center, single-arm study to establish the safety and feasibility of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
• Actual Study Start Date: March 26, 2019
• Actual Primary Completion Date: December 31, 2023
• Actual Study Completion Date: December 31, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Focused Ultrasound (FUS); The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.	Device: Focused ultrasound (FUS); FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.; Other Name: ExAblate, Type 2

Outcome Measures

Primary Outcome Measures :

1. Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ]
   The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE

Secondary Outcome Measures :

1. Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging [ Time Frame: At the time of each ExAblate MRgFUS procedure ]
   The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patient is eligible for adjuvant temozolomide (TMZ) treatment based on the current standard of care.
2. Men or women age between 18 and 80 years, inclusive.
3. Able and willing to give informed consent.
4. Grade IV glioma (GBM)
5. Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.
6. Karnofsky rating 70-100.
7. Able to communicate during the ExAblate BBBD (Blood Brain Barrier Disruption) procedure.
8. Able to attend all study visits (i.e., life expectancy of at least 3 months).

Exclusion Criteria:

1. Patients presenting with the following imaging characteristics:

   i. Evidence of acute intracranial hemorrhage.

2. The sonication pathway to the tumor involves:

   i. Extensive scalp sores. ii. Clips or other metallic implanted objects in the skull or the brain (brain implants)

3. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
4. Patients with cerebellar or brainstem tumors.
5. Patients with positive HIV status.
6. Significant depression not adequately controlled with medication and at potential risk of suicide.
7. Patient receiving bevacizumab (Avastin) therapy.
8. Patients receiving treatment with corticosteroid doses greater than dexamethasone 24 mg daily (or equivalent).
9. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy.

10. Cardiac disease or unstable hemodynamics including:

    i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.

11. Severe hypertension (diastolic BP > 100 on medication).
12. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment.
13. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
14. Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis.
15. History of drug or alcohol use disorder.
16. Active seizure disorder or epilepsy (seizures despite medical treatment).
17. Known sensitivity to gadolinium-based contrast agents.
18. Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.
19. Contraindications to MRI such as non-MRI-compatible implanted devices.
20. Large subjects not fitting comfortably into the MRI scanner.
21. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
22. Positive pregnancy test (women of childbearing potential).
23. Severely impaired renal function or on dialysis.
24. Cardiac shunt.
25. Subjects with evidence of cranial or systemic infection.
26. Subjects with significant liver dysfunction, e.g., history of cirrhosis or active hepatitis.

Contacts and Locations

Locations

United States, Maryland

University of Maryland

Baltimore, Maryland, United States, 21201

United States, Massachusetts

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

United States, Virginia

University of Virginia

Charlottesville, Virginia, United States, 22908

United States, West Virginia

West Virginia University

Morgantown, West Virginia, United States, 26506

Sponsors and Collaborators

InSightec

Investigators

• Principal Investigator: Graeme Woodworth, MD; University of Maryland

More Information

• Responsible Party: InSightec
• ClinicalTrials.gov Identifier: NCT03551249
• Other Study ID Numbers: BT008
• First Posted: June 11, 2018
• Last Update Posted: March 5, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:

Glioblastoma; Glioma; Astrocytoma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue